Revelation Cash Flow To Debt Ratio vs Cash Conversion Cycle Analysis

REVB Stock

USD 3.82 0.10 2.69%

Revelation Biosciences financial indicator trend analysis is much more than just breaking down Revelation Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Revelation Biosciences is a good investment. Please check the relationship between Revelation Biosciences Cash Flow To Debt Ratio and its Cash Conversion Cycle accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.

Cash Flow To Debt Ratio vs Cash Conversion Cycle

Cash Flow To Debt Ratio vs Cash Conversion Cycle Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Revelation Biosciences Cash Flow To Debt Ratio account and Cash Conversion Cycle. At this time, the significance of the direction appears to have pay attention.

The correlation between Revelation Biosciences' Cash Flow To Debt Ratio and Cash Conversion Cycle is -0.8. Overlapping area represents the amount of variation of Cash Flow To Debt Ratio that can explain the historical movement of Cash Conversion Cycle in the same time period over historical financial statements of Revelation Biosciences, assuming nothing else is changed. The correlation between historical values of Revelation Biosciences' Cash Flow To Debt Ratio and Cash Conversion Cycle is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Flow To Debt Ratio of Revelation Biosciences are associated (or correlated) with its Cash Conversion Cycle. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Conversion Cycle has no effect on the direction of Cash Flow To Debt Ratio i.e., Revelation Biosciences' Cash Flow To Debt Ratio and Cash Conversion Cycle go up and down completely randomly.

Correlation Coefficient

-0.8

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Cash Flow To Debt Ratio

Cash Conversion Cycle

Most indicators from Revelation Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Revelation Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.As of January 31, 2025, Selling General Administrative is expected to decline to about 3.9 M. In addition to that, Tax Provision is expected to decline to about 11.2 M

	2018	2019	2024	2025 (projected)
Net Interest Income	82.8M	92.9M	106.8M	81.1M
Tax Provision	9.4M	11.6M	13.3M	11.2M

Net Interest Income Tax Provision

Revelation Biosciences fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Accounts Payable	Cash	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Total Liab	Long Term Investments	Intangible Assets	Total Current Liabilities	Other Liab	Net Tangible Assets	Other Assets	Other Current Assets	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt	Short Term Debt	Other Current Liab	Non Current Assets Total	Non Currrent Assets Other
Total Assets		0.99	0.91	-0.05	0.77	-0.93	-0.85	-0.53	0.82	1.0	-0.79	0.87	1.0	-0.83	0.71	0.79	0.8	-0.77	0.64	0.83	0.11	0.4	0.99	-0.72	-0.29	-0.29
Total Stockholder Equity	0.99		0.93	0.0	0.76	-0.93	-0.79	-0.5	0.81	0.99	-0.72	0.82	0.99	-0.81	0.71	0.78	0.79	-0.75	0.66	0.82	0.1	0.38	0.97	-0.7	-0.28	-0.28
Retained Earnings	0.91	0.93		0.14	0.78	-0.85	-0.63	-0.5	0.86	0.9	-0.55	0.64	0.89	-0.75	0.8	0.81	0.83	-0.83	0.77	0.84	0.27	0.43	0.84	-0.8	-0.11	-0.11
Accounts Payable	-0.05	0.0	0.14		0.36	0.13	0.28	0.17	0.32	-0.06	0.3	-0.24	-0.07	-0.15	0.42	0.31	0.3	-0.01	0.53	0.29	0.6	0.03	-0.11	-0.02	-0.1	-0.1
Cash	0.77	0.76	0.78	0.36		-0.7	-0.68	-0.53	0.97	0.77	-0.66	0.7	0.77	-0.91	0.98	0.98	0.98	-0.81	0.94	0.98	0.68	0.42	0.75	-0.78	-0.34	-0.33
Long Term Debt	-0.93	-0.93	-0.85	0.13	-0.7		0.86	0.51	-0.75	-0.93	0.77	-0.83	-0.93	0.84	-0.66	-0.73	-0.74	0.68	-0.59	-0.76	-0.09	-0.2	-0.92	0.63	0.28	0.28
Net Receivables	-0.85	-0.79	-0.63	0.28	-0.68	0.86		0.64	-0.68	-0.85	0.99	-0.99	-0.88	0.8	-0.58	-0.7	-0.71	0.72	-0.45	-0.73	-0.11	-0.33	-0.9	0.68	0.25	0.25
Good Will	-0.53	-0.5	-0.5	0.17	-0.53	0.51	0.64		-0.54	-0.53	0.7	-0.58	-0.54	0.48	-0.51	-0.55	-0.56	0.77	-0.43	-0.56	-0.26	-0.83	-0.53	0.76	-0.03	-0.03
Short Term Investments	0.82	0.81	0.86	0.32	0.97	-0.75	-0.68	-0.54		0.82	-0.64	0.69	0.81	-0.92	0.98	0.99	0.99	-0.85	0.95	1.0	0.66	0.45	0.78	-0.81	-0.33	-0.33
Total Liab	1.0	0.99	0.9	-0.06	0.77	-0.93	-0.85	-0.53	0.82		-0.79	0.88	1.0	-0.83	0.71	0.79	0.8	-0.77	0.63	0.83	0.11	0.4	0.99	-0.72	-0.29	-0.29
Long Term Investments	-0.79	-0.72	-0.55	0.3	-0.66	0.77	0.99	0.7	-0.64	-0.79		-0.97	-0.82	0.75	-0.55	-0.67	-0.68	0.72	-0.41	-0.69	-0.13	-0.41	-0.85	0.69	0.21	0.21
Intangible Assets	0.87	0.82	0.64	-0.24	0.7	-0.83	-0.99	-0.58	0.69	0.88	-0.97		0.9	-0.8	0.59	0.72	0.72	-0.72	0.46	0.74	0.1	0.35	0.93	-0.68	-0.27	-0.27
Total Current Liabilities	1.0	0.99	0.89	-0.07	0.77	-0.93	-0.88	-0.54	0.81	1.0	-0.82	0.9		-0.83	0.71	0.79	0.8	-0.78	0.63	0.83	0.11	0.4	0.99	-0.72	-0.29	-0.29
Other Liab	-0.83	-0.81	-0.75	-0.15	-0.91	0.84	0.8	0.48	-0.92	-0.83	0.75	-0.8	-0.83		-0.88	-0.93	-0.93	0.7	-0.83	-0.93	-0.52	-0.25	-0.83	0.65	0.56	0.56
Net Tangible Assets	0.71	0.71	0.8	0.42	0.98	-0.66	-0.58	-0.51	0.98	0.71	-0.55	0.59	0.71	-0.88		0.98	0.98	-0.82	0.98	0.98	0.76	0.44	0.67	-0.79	-0.29	-0.29
Other Assets	0.79	0.78	0.81	0.31	0.98	-0.73	-0.7	-0.55	0.99	0.79	-0.67	0.72	0.79	-0.93	0.98		1.0	-0.85	0.94	1.0	0.69	0.45	0.77	-0.81	-0.35	-0.35
Other Current Assets	0.8	0.79	0.83	0.3	0.98	-0.74	-0.71	-0.56	0.99	0.8	-0.68	0.72	0.8	-0.93	0.98	1.0		-0.86	0.94	1.0	0.68	0.46	0.78	-0.83	-0.34	-0.34
Other Stockholder Equity	-0.77	-0.75	-0.83	-0.01	-0.81	0.68	0.72	0.77	-0.85	-0.77	0.72	-0.72	-0.78	0.7	-0.82	-0.85	-0.86		-0.73	-0.86	-0.47	-0.7	-0.74	0.99	-0.06	-0.06
Total Current Assets	0.64	0.66	0.77	0.53	0.94	-0.59	-0.45	-0.43	0.95	0.63	-0.41	0.46	0.63	-0.83	0.98	0.94	0.94	-0.73		0.93	0.79	0.38	0.58	-0.7	-0.31	-0.31
Common Stock	0.83	0.82	0.84	0.29	0.98	-0.76	-0.73	-0.56	1.0	0.83	-0.69	0.74	0.83	-0.93	0.98	1.0	1.0	-0.86	0.93		0.64	0.46	0.81	-0.82	-0.33	-0.33
Property Plant Equipment	0.11	0.1	0.27	0.6	0.68	-0.09	-0.11	-0.26	0.66	0.11	-0.13	0.1	0.11	-0.52	0.76	0.69	0.68	-0.47	0.79	0.64		0.26	0.08	-0.47	-0.19	-0.19
Short Long Term Debt	0.4	0.38	0.43	0.03	0.42	-0.2	-0.33	-0.83	0.45	0.4	-0.41	0.35	0.4	-0.25	0.44	0.45	0.46	-0.7	0.38	0.46	0.26		0.38	-0.69	0.09	0.09
Short Term Debt	0.99	0.97	0.84	-0.11	0.75	-0.92	-0.9	-0.53	0.78	0.99	-0.85	0.93	0.99	-0.83	0.67	0.77	0.78	-0.74	0.58	0.81	0.08	0.38		-0.69	-0.32	-0.32
Other Current Liab	-0.72	-0.7	-0.8	-0.02	-0.78	0.63	0.68	0.76	-0.81	-0.72	0.69	-0.68	-0.72	0.65	-0.79	-0.81	-0.83	0.99	-0.7	-0.82	-0.47	-0.69	-0.69		-0.12	-0.12
Non Current Assets Total	-0.29	-0.28	-0.11	-0.1	-0.34	0.28	0.25	-0.03	-0.33	-0.29	0.21	-0.27	-0.29	0.56	-0.29	-0.35	-0.34	-0.06	-0.31	-0.33	-0.19	0.09	-0.32	-0.12		1.0
Non Currrent Assets Other	-0.29	-0.28	-0.11	-0.1	-0.33	0.28	0.25	-0.03	-0.33	-0.29	0.21	-0.27	-0.29	0.56	-0.29	-0.35	-0.34	-0.06	-0.31	-0.33	-0.19	0.09	-0.32	-0.12	1.0

Click cells to compare fundamentals

Revelation Biosciences Account Relationship Matchups

Revelation Biosciences fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	4.6M	2.0M	5.5M	12.2M	11.0M	10.4M
Total Stockholder Equity	3.4M	(99.5K)	1.1M	6.6M	6.0M	5.7M
Retained Earnings	(2.5M)	(14.5M)	(25.3M)	(25.5M)	(22.9M)	(21.8M)
Accounts Payable	865.9K	596.3K	554.2K	1.4M	1.2M	812.7K
Cash	4.5M	1.3M	5.3M	12.0M	10.8M	10.3M
Total Liab	1.2M	2.1M	4.5M	5.6M	5.0M	4.8M
Total Current Liabilities	1.2M	2.1M	4.5M	5.6M	5.0M	4.8M
Other Liab	5.9M	8.0M	76.4M	50.7M	58.3M	32.4M
Net Tangible Assets	234.4M	273.9M	3.0M	(7.8M)	(7.0M)	(6.7M)
Other Current Assets	128K	637.3K	73.1K	155.8K	140.2K	133.2K
Other Stockholder Equity	5.5M	14.4M	26.4M	32.1M	36.9M	38.8M
Total Current Assets	4.6M	1.9M	5.4M	12.1M	10.9M	10.4M
Common Stock	2.3K	2.3K	683.0	265.0	238.5	226.58
Other Current Liab	342.9K	1.5M	3.9M	4.2M	4.8M	5.1M
Non Current Assets Total	73.5M	130.1K	90.1K	65.1K	58.6K	55.6K
Liabilities And Stockholders Equity	4.6M	2.0M	5.5M	12.2M	14.0M	14.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:

How To Invest In Revelation

Details

Is Revelation Stock a good investment?

Details

What is Revelation Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.

You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(280.48)

Return On Assets

(0.51)

Return On Equity

(2.70)

The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Revelation Cash Flow To Debt Ratio vs Cash Conversion Cycle Analysis

Cash Flow To Debt Ratio vs Cash Conversion Cycle

Cash Flow To Debt Ratio vs Cash Conversion Cycle Correlation Analysis

Correlation Coefficient

Cash Flow To Debt Ratio

Cash Conversion Cycle

Revelation Biosciences fundamental ratios Correlations

Revelation Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Revelation Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Total Assets
Common Stock	+ 1.0	Short Term Investments
Total Current Liabilities	+ 1.0	Total Liab
Other Current Assets	+ 1.0	Other Assets
Common Stock	+ 1.0	Other Assets

Intangible Assets	- 0.99	Net Receivables
Intangible Assets	- 0.97	Long Term Investments
Common Stock	- 0.93	Other Liab
Other Current Assets	- 0.93	Other Liab
Other Assets	- 0.93	Other Liab
Total Current Liabilities	- 0.93	Long Term Debt